Vitruvia Medical (MUN:991) - Share price, News & Analysis

991 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	6/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

991 Stock Overview

Vitruvia Medical AG operates as a technology company in the healthcare sector.

Rewards

Trading at 95% below our estimate of its fair value

Earnings are forecast to grow 77.72% per year

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap (€20M)

Vitruvia Medical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vitruvia Medical
Historical stock prices
Current Share Price	€11.50
52 Week High	€22.00
52 Week Low	€11.00
Beta	0
1 Month Change	0%
3 Month Change	-20.69%
1 Year Change	-47.73%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-49.11%

Shareholder Returns

	991	DE Life Sciences	DE Market
7D	0%	0.6%	1.2%
1Y	-47.7%	-12.0%	-12.2%

Return vs Industry: 991 underperformed the German Life Sciences industry which returned -12% over the past year.

Return vs Market: 991 underperformed the German Market which returned -12.2% over the past year.

Price Volatility

Is 991's price volatile compared to industry and market?
991 volatility
991 Average Weekly Movement	5.2%
Life Sciences Industry Average Movement	7.7%
Market Average Movement	6.4%
10% most volatile stocks in DE Market	10.7%
10% least volatile stocks in DE Market	3.5%

Stable Share Price: 991 is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 991's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	https://www.vitruvia-med.com

Vitruvia Medical AG operates as a technology company in the healthcare sector. It supplies circular systems for medical devices primarily in robot-assisted surgery. The company is based in Anglikon, Switzerland.

Vitruvia Medical Fundamentals Summary

How do Vitruvia Medical's earnings and revenue compare to its market cap?
991 fundamental statistics
Market Cap	€20.36m
Earnings (TTM)	-€1.54m
Revenue (TTM)	€5.77m

3.5x

P/S Ratio

-13.2x

P/E Ratio

Is 991 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
991 income statement (TTM)
Revenue	€5.77m
Cost of Revenue	€3.74m
Gross Profit	€2.03m
Other Expenses	€3.57m
Earnings	-€1.54m

Last Reported Earnings

Dec 31, 2020

Next Earnings Date

n/a

Earnings per share (EPS)	-0.87
Gross Margin	35.13%
Net Profit Margin	-26.76%
Debt/Equity Ratio	0.0%

How did 991 perform over the long term?

See historical performance and comparison

Valuation

Is Vitruvia Medical undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 991 (€11.5) is trading below our estimate of fair value (€229.71)

Significantly Below Fair Value: 991 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: 991 is unprofitable, so we can't compare its PE Ratio to the European Life Sciences industry average.

PE vs Market: 991 is unprofitable, so we can't compare its PE Ratio to the German market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 991's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 991 is overvalued based on its PB Ratio (5.2x) compared to the XE Life Sciences industry average (3.3x).

Future Growth

How is Vitruvia Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

6/6

Future Growth Score 6/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

77.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 991 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.05%).

Earnings vs Market: 991 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 991's is expected to become profitable in the next 3 years.

Revenue vs Market: 991's revenue (37.1% per year) is forecast to grow faster than the German market (4.9% per year).

High Growth Revenue: 991's revenue (37.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 991's Return on Equity is forecast to be very high in 3 years time (48%).

Past Performance

How has Vitruvia Medical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

30.4%

Historical Pharmaceuticals & Biotech annual earnings growth

Earnings and Revenue History

Quality Earnings: 991 is currently unprofitable.

Growing Profit Margin: 991 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Unable to establish if 991's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare 991's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 991 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (50.8%).

Return on Equity

High ROE: 991 has a negative Return on Equity (-39.8%), as it is currently unprofitable.

Financial Health

How is Vitruvia Medical's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: 991's short term assets (€1.9M) do not cover its short term liabilities (€3.2M).

Long Term Liabilities: 991's short term assets (€1.9M) exceed its long term liabilities (€793.0K).

Debt to Equity History and Analysis

Debt Level: 991 is debt free.

Reducing Debt: 991 has not had any debt for past 5 years.

Debt Coverage: 991 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 991 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is Vitruvia Medical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 991's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 991's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 991's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 991's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 991 has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Vitruvia Medical has no CEO, or we have no data on them.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/15 00:00
End of Day Share Price	2022/05/13 00:00
Earnings	2020/12/31
Annual Earnings	2020/12/31